Clinical improvement of diffuse lymphangiomatosis with pegylated interferon alfa-2b therapy: Case report and review of the literature
Clinical improvement of diffuse lymphangiomatosis with pegylated interferon alfa-2b therapy: Case report and review of the literature
复制标题
DOI：
10.1080/08880010701533603
复制
发表时间：
2007-01-01
影响因子：
1.7
通讯作者：
Kondo, Naomi
中科院分区：
文献类型：
--
作者：
Ozeki, Michio;Funato, Michinori;Kondo, Naomi
弥漫性淋巴管瘤病是一种非常罕见的先天性疾病，其特征是骨骼组织、脾、肝、纵隔和/或肺中弥漫性或多灶性淋巴管瘤。预后通常较差，特别是对于有胸部病变的儿童，该病的治疗方法存在争议。作者报告了一名 9 岁男孩患有弥漫性淋巴管瘤病，累及胸部并伴有胸腔积液、脾脏和全身骨骼。该患者接受了聚乙二醇干扰素 alfa-2b 治疗，取得了良好的临床和放射学改善。
Diffuse lymphangiomatosis is a very rare congenital disease, characterized by diffuse or miltifocal lymphangioma in the skeletal tissue, spleen, liver, mediastinum, and/or lung. The prognosis is usually poor, especially for children with thoracic lesion, and treatments for the disease are controversial. The authors report a 9-year-old boy with, diffuse lymphangiomatosis involving the thorax with pleural effusions, the spleen, and systemic bone. The patient was treated with pegylated interferon, alfa-2b, and achieved good clinical and radiological improvement.